AstraZeneca's Klygefa wins EU approval for rare muscle disorder
AstraZeneca's Alexion unit won EU approval for Klygefa (gefurulimab), a once-weekly self-injected treatment for adults with generalised myasthenia gravis who are anti-AChR antibody positive. It becomes the region's first dual-binding nanobody C5 inhibitor, backed by Phase III PREVAIL results.
- Original source: rttnews.com.
- The source published it on Nov 15, 2026 at 11:39 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
AstraZeneca's rare disease arm Alexion has cleared European regulators with Klygefa (gefurulimab), which is now approved in the EU for adults living with generalised myasthenia gravis, or gMG. The green light covers use as an add-on to standard therapy in adults who test positive for anti-acetylcholine receptor antibodies.
Klygefa is the first and only dual-binding nanobody C5 inhibitor available in the region, according to AstraZeneca. It is given once a week through subcutaneous self-injection with an autoinjector, a setup the company says delivers rapid and sustained disease control.
The European Commission decision followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. It rests on the pivotal PREVAIL Phase III trial, which tested the drug in a condition marked by reduced muscle function and severe muscle weakness.
Klygefa hit its primary endpoint in PREVAIL, improving patients' Myasthenia Gravis Activities of Daily Living total score from baseline at week 26 compared with placebo. AstraZeneca said the drug was generally well-tolerated, with a safety profile in line with earlier trials of C5 inhibitors eculizumab and ravulizumab in gMG.
Tobias Ruck, director of the Department of Neurology at BG University Hospital Bergmannsheil Bochum, Ruhr-University Bochum, and an investigator in the trial, said clinical management of gMG is complex because symptoms, severity and trajectory can vary widely. He pointed to PREVAIL data showing rapid and durable disease control starting as early as week one and lasting through one year, plus what he called the added autonomy of weekly self-administration.
Klygefa is already approved in the US, Japan and other countries for certain adults with gMG, and regulatory submissions built on the PREVAIL results are under review in China and additional markets. In overnight trading on the NYSE, AstraZeneca shares (AZN) were at $184.68, up 0.12 percent.
TopicsAstraZeneca · Alexion · Klygefa · gefurulimab · European Medicines Agency · Tobias Ruck · AZN · PREVAIL Phase III trial
Source: rttnews.com
Written by AI from verified reporting. Not financial advice.

